JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Eliminating specific cells without damaging other cells is extremely difficult, especially in established tissue, yet there is an urgent need for a cell elimination method in the tissue engineering field. Here, we present a method for specific cell elimination from a mixed 3D cell culture using near infrared photoimmunotherapy (NIR-PIT).

Abstract

Recent developments in tissue engineering offer innovative solutions for many diseases. For example, tissue engineering using induced pluripotent stem cell (iPS) emerged as a new method in regenerative medicine. Although this tissue regeneration is promising, contamination with unwanted cells during tissue cultures is a major concern. Moreover, there is a safety concern regarding tumorigenicity after transplantation. Therefore, there is an urgent need for eliminating specific cells without damaging other cells that need to be protected, especially in established tissue. Here, we present a method for specific cell elimination from a mixed 3D cell culture in vitro with near infrared photoimmunotherapy (NIR-PIT) without damaging non-targeted cells. This technique enables the elimination of specific cells from mixed cell cultures or tissues.

Introduction

Eliminating specific cells without damaging other cells is extremely difficult, especially in established tissue, and there is an urgent need for a cell elimination method in the tissue engineering field. Nowadays in the field of regenerative medicine, tissue cultures using embryonic stem cells (ES), pluripotent stem cells (PSCs), or induced pluripotent stem cell (iPS) are promising materials1-3.

Although this tissue regeneration is promising, contamination with unwanted cells is a major concern. Moreover, there is a safety concern of tumorigenicity after transplantation4,5. Although many studies have focused on these issues to eliminate specific cells, especially in regenerative medicine6-8, no practical method has been developed.

Near infrared photoimmunotherapy (NIR-PIT) is a treatment based on an antibody-photoabsorber conjugate (APC). An APC consists of a cell-specific monoclonal antibody (mAb) and a photoabsorber, IR700. IR700 is a hydrophilic silica-phthalocyanine derivative and does not induce phototoxicity by itself9. IR700 is covalently conjugated to the antibody via amide residues on the side chain of lysine molecules. The APC binds target molecules on the cell membrane and then induces nearly immediate cell necrosis after exposure to NIR light at 690 nm. During the exposure to NIR-light, the cellular membrane ruptures leading to cell death9-14. NIR-PIT has proven to be effective with multiple antibodies or antibody fragments, including anti-EGFR, anti-HER2, anti-PSMA, anti-CD25, anti-mesothelin, anti-GPC3, and anti-CEA15-21. Therefore, NIR-PIT can be used against a wide variety of target molecules. Moreover, NIR-PIT is a well-controlled treatment that allows selective treatment of specific regions by restricting the NIR-light irradiation18,22.

Here, we present a method of specific cell elimination using NIR-PIT from mixed 3D cultures.

Access restricted. Please log in or start a trial to view this content.

Protocol

Note: The following protocol describes the necessary steps to eliminate specific cells using NIR-PIT. Controls and other details about NIR-PIT and cell viability can be found elsewhere18.

1. Conjugation of IR700 to Monoclonal Antibodies (mAb)

  1. Prepare mAb of interest at 2-5 mg/ml in 0.1 M Na2HPO4 (pH 8.6) solution.
  2. Mix 6.8 nmol of mAb with 30.8 nmol of 10 mM IR700 in 0.1 M Na2HPO4 solution (pH 8.6) in a microcentrifuge tube and incubate at RT for 1 hr, covered with aluminum foil.
  3. Wash the PD-10 column (see Table of Materials/Equipment) with 15 ml PBS, twice. Load the sample from step 1.2.
  4. Purify the mixture via the PD-10 column by PBS elution according to manufacturer's instructions.
    Note: Here, the elution was along the band color of IR700. For a 300 µl sample, PBS elution fraction is typically between 2.5 ml to 4.4 ml.
  5. Determine the protein concentration with Coomassie staining by measuring the absorption at 595 nm with a spectrophotometer9. Determine the concentration of IR700 with absorption at 689 nm to confirm the number of fluorophore molecules conjugated to each mAb molecule9.
    Note: It is important to determine an optimal conjugation number of IR700 molecules in 1 mAb with a spectrophotometer. Generally, around 3 IR700 molecules in 1 mAb molecule is optimal for both in vitro and in vivo work. HPLC and SDS-PAGE methods can be used to confirm whether the mAb and IR700 are bound or not.
  6. Store at 4 °C after determining the protein concentration.

2. Preparation of Mixed 3D Cell Culture (Mixed Spheroid)

  1. Apply sterile water (around 1 ml) into the plate reservoir section of hanging drop plates.
  2. Prepare various ratios of the cell types of interest — A431-luc-GFP cells and 3T3-RFP cells — with each sample containing 5,000 cells total, suspended in 50 µl of culture media.
    Note: Prepare 1:100, 10: 100, 25:100, 50:100, etc. ratios of cells types of interest in culture media depending on the cell-type.
  3. Incubate the mix for 5-7 days in the 96 well hanging drop plate in a humidified incubator at 37 °C and 5% carbon dioxide. Change the culture media every 2 days. Note: To make the 3D spheroid precisely, handle the plate gently, as drops containing cells fall off easily before forming 3D shapes.
  4. Observe the morphology and size of the spheroids using an inverted brightfield microscope at 10X - 40X magnification. Note: Although it depends on cell types and the size of hanging-drop, ensure that the diameter of the spheroid is around 400-600 µm after 7 days of incubation in the 96 well hanging drop plate.

3. In Vitro NIR-PIT for Mixed 3D Cell Culture

  1. Change the media of the hanging drop plates to 10 µg/ml antibody-photoabsorber conjugate (APC) containing media, and incubate for 6 hr in a humidified incubator at 37 °C and 5% carbon dioxide.
  2. After 6 hr incubation, wash the spheroid twice with fresh culture media (phenol red free). Gently transfer the spheroid to a glass-bottomed 50 mm dish with 100 µl fresh phenol red free culture media using a sterile 200 µl pipette tip with the tip cut off. Place one spheroid in each dish.
  3. Observe the spheroid with an inverted brightfield microscope to detect the change of morphology. To observe the optical reporters (e.g., GFP and RFP) use fluorescence microscope with the following filter settings: GFP — 469 nm excitation filter, and 525 nm emission filter; RFP — 559 nm excitation filter, and 630 nm emission filter.
  4. Place the light-emitting diode (LED) above the glass-bottomed dish for irradiation.
    Note: Spheroids can be exposed to NIR light either on the microscope or in the laminar hood.
    1. Measure the power density of the NIR-light with an optical power meter9. According to this measurement, irradiate NIR-light via light-emitting diodes (LEDs) which emit light at wavelengths of 670 to 710 nm at 2 J/cm2.
      Note: LED light can penetrate maximum depth of approximately 5 inches. Cytotoxic effects of NIR-PIT is dependent only on given energy regardless of power density and duration of exposure23.
  5. After irradiation, transfer the spheroid into a new hanging drop plate with 50 µl of fresh culture media and incubate for 1 day in a humidified incubator at 37 °C and 5% carbon dioxide.
  6. Gently transfer the spheroid to a glass-bottomed dish with 100 µl of fresh culture media (phenol red free) using a sterile 200 µl pipette tip with the tip cut off. Observe the spheroid with a fluorescence microscope 1 day after NIR-PIT using filter settings described in step 3.3.
    1. Detect dead cells by adding propidium iodide to the media at a final concentration of 2 µg/ml, or by loss of cytoplasmic GFP-fluorescence using a fluorescence microscope (Figure 2B)14,18,22.
  7. Repeat steps 3.1-3.6 if target cells are not completely eliminated.

Access restricted. Please log in or start a trial to view this content.

Results

To optically monitor the effect of NIR-PIT, the A431 cell line, which overexpresses EGFR, was genetically modified to also express GFP and luciferase (A431-luc-GFP). As a non-target of NIR-PIT, the Balb/3T3 cell line was optically modified to express RFP (3T3-RFP). The APC, panitumumab-IR700 (pan-IR700), was synthesized. Mixed spheroids, which were composed of various ratios of cells (A431-luc-GFP and 3T3-RFP) were fabricated according to this protocol (Figure 1). Repeate...

Access restricted. Please log in or start a trial to view this content.

Discussion

We demonstrate a method of specific cell elimination from a mixed 3D cell culture without damage to non-target cells by using NIR-PIT. So far, there is no practical method of cell elimination once the tissue is established or after transplantation. Thus, NIR-PIT is a promising method to accomplish this. This technique could also be utilized in vivo18,22, since APCs show similar pharmacokinetics as mAb itself. The target cell type can be adapted with various APC. Various antibodies or antibody...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Access restricted. Please log in or start a trial to view this content.

Materials

NameCompanyCatalog NumberComments
IRDye 700DX Ester Infrared DyeLI-COR Bioscience (Lincoln, NE, USA)929-70011
Na2HPO4SIGMA-ALDRICH (St. Louis, MO, USA)S9763
Sephadex G25 column (PD-10) GE Healthcare (Piscataway, NJ, USA)17-0851-01
Coomassie (bradford) Plus protein assayThermo Fisher Scientific Inc (Waltham, MA, USA)PI-23200
Perfecta3D 96-Well hanging Drop Plates3D Biomatrix Inc (Ann Arbor, MI, USA)HDP1096-8
Optical power meterThorlabs (Newton, NJ, USA)PM100
LED: L690-66-60Marubeni America Co. (Santa Clara, CA, USA)L690-66-60
Vectibix (panitumumab)Amgen (Thousand Oaks, CA, USA)
35 mm glass bottom dish, dish size 35 mm, well size 10 mmCellvis (Mountain View, CA, USA)D35-10-0-N

References

  1. Robinton, D. A., Daley, G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature. 481 (7381), 295-305 (2012).
  2. Yamanaka, S. Induced pluripotent stem cells: past, present, and future. Cell stem cell. 10 (6), 678-684 (2012).
  3. Birchall, M. A., Seifalian, A. M. Tissue engineering's green shoots of disruptive innovation. Lancet. 6736 (14), 11-12 (2014).
  4. Ben-David, U., Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer. 11 (4), 268-277 (2011).
  5. Hanna, J. H., Saha, K., Jaenisch, R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell. 143 (4), 508-525 (2010).
  6. Lee, M. -O., Moon, S. H., et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc. Natl. Acad. Sci. U.S.A. 110 (35), 3281-3290 (2013).
  7. Miura, K., Okada, Y., et al. Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 27 (8), 743-745 (2009).
  8. Tang, C., Lee, A. S., et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat. Biotechnol. 29 (9), 829-834 (2011).
  9. Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L. Cancer cell - selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17 (12), 1685-1691 (2011).
  10. Mitsunaga, M., Nakajima, T., Sano, K., Kramer-Marek, G., Choyke, P. L., Kobayashi, H. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 12 (1), 345(2012).
  11. Nakajima, T., Sano, K., Mitsunaga, M., Choyke, P. L., Kobayashi, H. Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging. Cancer Res. 72 (18), 4622-4628 (2012).
  12. Sano, K., Mitsunaga, M., Nakajima, T., Choyke, P. L., Kobayashi, H. Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET. J. Nucl. Med. 54 (5), 770-775 (2013).
  13. Sato, K., Watanabe, R., et al. Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol. Oncol. 8 (3), 620-632 (2014).
  14. Sato, K., Nagaya, T., Mitsunaga, M., Choyke, P. L., Kobayashi, H. Near infrared photoimmunotherapy for lung metastases. Cancer Lett. 365 (1), 112-121 (2015).
  15. Sato, K., Hanaoka, H., Watanabe, R., Nakajima, T., Choyke, P. L., Kobayashi, H. Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer. Mol. Cancer Ther. 14 (8), 141-150 (2014).
  16. Sato, K., Choyke, P. L., Kobayashi, H. Photoimmunotherapy of Gastric Cancer Peritoneal Carcinomatosis in a Mouse Model. PloS one. 9 (11), 113276(2014).
  17. Sato, K., Nagaya, T., Choyke, P. L., Kobayashi, H. Near Infrared Photoimmunotherapy in the Treatment of Pleural Disseminated NSCLC Preclinical Experience. Theranostics. 5 (7), 698-709 (2015).
  18. Sato, K., Nakajima, T., Choyke, P. L., Kobayashi, H. Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv. 5, 25105-25114 (2015).
  19. Watanabe, R., Hanaoka, H., et al. Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies. J. Nucl. Med. 56 (1), 140-144 (2014).
  20. Nakajima, T., Sano, K., Choyke, P. L., Kobayashi, H. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 3 (6), 357-365 (2013).
  21. Shirasu, N., Yamada, H. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int J Cancer. 135 (11), 1-14 (2014).
  22. Sato, K., Nagaya, T., Nakamura, Y., Harada, T., Choyke, P. L., Kobayashi, H. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget. 6 (23), 19747-19758 (2015).
  23. Nakajima, T., Sato, K., et al. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC cancer. 14 (1), 389(2014).
  24. Klimanskaya, I., Rosenthal, N., Lanza, R. Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat. Rev. Drug Discov. 7 (2), 131-142 (2008).
  25. Burmester, G. R., Feist, E., Dörner, T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 10 (2), 77-88 (2014).
  26. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12 (4), 252-264 (2012).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

3D Cell CultureNear Infrared PhotoimmunotherapySelective Cell EliminationIR700 ConjugationMonoclonal AntibodySpheroidTissue EngineeringRegenerative Medicine

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved